Studies on Shokyo, Kanzo, and Keihi in Kakkonto Medicine on Prostaglandin E<sub>2</sub> Production in Lipopolysaccharide-Treated Human Gingival Fibroblasts

<div>The contribution of PLA<sub>2</sub> isoforms in HGFs. HGFs were treated with LPS (10 ng/mL) and PLA<sub>2</sub> inhibitor for 24 h. Concentrations of PGE<sub>2</sub> were measured by ELISA, adjusted by cell number, and expressed as pg per 10,000 cells (mean ± SD, <svg height="8.55521pt" id="M15" style="vertical-align:-0.2063904pt" version="1.1" viewbox="-0.0498162 -8.34882 27.8368 8.55521" width="27.8368pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M495 86L479 114C446 82 419 66 409 66C401 66 401 72 406 97C420 166 436 231 453 297C489 435 454 448 428 448C406 448 384 439 354 422C305 394 222 327 161 247H159L183 345C200 415 194 448 173 448C143 448 82 410 23 351L38 325C64 349 95 371 105 371C111 371 116 365 109 336L25 -4L31 -12C50 -4 77 3 107 9C119 69 132 122 145 168C197 254 321 381 370 381C387 381 393 374 378 305L329 95C309 17 320 -12 345 -12C372 -12 430 19 495 86Z" id="g113-111"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="502" vert-adv-y="502"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,10.158,0)"><path d="M535 323V373H52V323H535ZM535 138V188H52V138H535Z" id="g117-34"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="587" vert-adv-y="587"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,21.421,0)"><path d="M456 178V225H360V632H320C217 496 115 347 20 206V178H280V106C280 40 276 34 189 27V0H445V27C364 34 360 39 360 106V178H456ZM280 225H82C149 335 214 431 278 520H280V225Z" id="g113-53"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="480" vert-adv-y="480"></glyph.data></g></svg>). CAY10502, cPLA<sub>2</sub><svg height="6.1673pt" id="M16" style="vertical-align:-0.2063904pt" version="1.1" viewbox="-0.0498162 -5.96091 7.51131 6.1673" width="7.51131pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M545 106L524 126C493 85 467 65 455 65C438 65 427 113 405 238C448 295 498 362 543 439L533 448L478 435C453 386 423 331 398 295H395C370 404 347 448 282 448C169 448 23 309 23 153C23 54 65 -12 128 -12C203 -12 283 70 339 155H341C360 29 380 -12 411 -12C444 -12 491 11 545 106ZM333 204C265 95 210 54 169 54C137 54 113 96 113 171C113 302 191 405 252 405C301 405 318 306 333 204Z" id="g113-223"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="568" vert-adv-y="568"></glyph.data></g></svg> inhibitor (100 nM); BEL (bromoenol lactone), iPLA<sub>2</sub> inhibitor (20 <i>μ</i>M); Thio-PC (thioetheramide-PC), sPLA<sub>2</sub> inhibitor (20 <i>μ</i>M); and ZR (shokyo, 100 <i>μ</i>g/mL) a positive control.</div>

International Scholarly Research Notices

fig3

Figure 3

Figure 3: Studies on Shokyo, Kanzo, and Keihi in Kakkonto Medicine on Prostaglandin E<sub>2</sub> Production in Lipopolysaccharide-Treated Human Gingival Fibroblasts 

Figure 3 | Studies on Shokyo, Kanzo, and Keihi in Kakkonto Medicine on Prostaglandin E2 Production in Lipopolysaccharide-Treated Human Gingival Fibroblasts 